News for Gerresheimer AG (GXI.DE)

Q4 Organic Revenue Growth: 5.4%Q4 Adjusted EBITDA Growth: 6.4%Q4 Adjusted Earnings Per Share Growth: 6.7%Full Year Organic Revenue Growth: 2.9%Full Year Adjust

Feb 26, 2025 / 09:00AM GMTOperator Ladies and gentlemen, welcome to the publication Q4 and full year 2024 results conference call. I am Vicky, the Chorus Call o

Gerresheimer AG (OTCPK:GRRMF) Q4 2024 Results Conference Call February 26, 2025 4:00 AM ETCompany ParticipantsGuido Pickert - Investor RelationsDietmar...

Germany stocks mixed at close of trade; DAX up 0.24%

Germany stocks higher at close of trade; DAX up 0.49%

Germany stocks mixed at close of trade; DAX down 0.18%

Germany stocks mixed at close of trade; DAX down 0.18%

Germany stocks mixed at close of trade; DAX down 0.23%

Germany stocks mixed at close of trade; DAX down 0.27%

Germany stocks lower at close of trade; DAX down 0.45%

Germany stocks mixed at close of trade; DAX up 1.44%

The syringes market is expected to exceed USD 24,101 million in 2024. The market is expected to exceed USD 56,694.2 million by 2033, with a robust CAGR of...

Germany stocks higher at close of trade; DAX up 0.02%

The Needle-Free Injector Market is growing rapidly along with the escalating requirements of pain-free drug delivery systems, greater needle-phobic...

Germany stocks higher at close of trade; DAX up 0.38%

Germany stocks higher at close of trade; DAX up 0.80%

Germany stocks higher at close of trade; DAX up 0.66%

Global Medical Device Contract Manufacturing Market size was valued at USD 70.83 billion in 2023 to USD 167.99 billion by 2031, growing at a CAGR of 11.4%...

Increased demand for biologics and biosimilars is driving the demand for dual chamber prefilled syringes....